Glaxo Wellcome Zofran ODT
Executive Summary
Odansetron orally disintegrating tablets approved Jan. 27 for prevention of chemotherapy and radiation-induced nausea and vomiting, and prevention of postoperative nausea and vomiting. NDA 20-781 was received July 2, 1997. Zofran is currently marketed in an injectable and conventional oral formulation
Odansetron orally disintegrating tablets approved Jan. 27 for prevention of chemotherapy and radiation-induced nausea and vomiting, and prevention of postoperative nausea and vomiting. NDA 20-781 was received July 2, 1997. Zofran is currently marketed in an injectable and conventional oral formulation. |